Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J E Cortes

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Leukemia|April 4, 2008
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosisA Quintás-Cardama, W Tong, H Kantarjian, et al.
Blood|December 12, 2001
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blastsE H Estey, P F Thall, J E Cortes, et al.
Blood Cancer Journal|February 4, 2017
Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemiaZ Chen, L J Medeiros, H M Kantajian, et al.
Revista De Neurologia|September 21, 2018
[Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma]O Y Bello-Chavolla, J E Cortes-Arroyo, A Vargas-Vazquez, et al.
Leukemia|May 2, 2015
Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitorsW Wang, J E Cortes, P Lin, et al.
Leukemia|December 22, 2015
Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trialsP D le Coutre, T P Hughes, F-X Mahon, et al.
Leukemia|February 4, 2016
Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyZ Chen, J E Cortes, J L Jorgensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemiaF J Giles, J E Cortes, S D Baker, et al.
Leukemia|January 8, 2010
Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cellsJ A Burger, N S Velev, E J Jabbour, et al.
Blood Cancer Journal|July 15, 2017
Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemiaZ Gong, L J Medeiros, J E Cortes, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Leukemia|April 4, 2008
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosisA Quintás-Cardama, W Tong, H Kantarjian, et al.
Blood|December 12, 2001
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blastsE H Estey, P F Thall, J E Cortes, et al.
Blood Cancer Journal|February 4, 2017
Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemiaZ Chen, L J Medeiros, H M Kantajian, et al.
Revista De Neurologia|September 21, 2018
[Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma]O Y Bello-Chavolla, J E Cortes-Arroyo, A Vargas-Vazquez, et al.
Leukemia|May 2, 2015
Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitorsW Wang, J E Cortes, P Lin, et al.
Leukemia|December 22, 2015
Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trialsP D le Coutre, T P Hughes, F-X Mahon, et al.
Leukemia|February 4, 2016
Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyZ Chen, J E Cortes, J L Jorgensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemiaF J Giles, J E Cortes, S D Baker, et al.
Leukemia|January 8, 2010
Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cellsJ A Burger, N S Velev, E J Jabbour, et al.
Blood Cancer Journal|July 15, 2017
Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemiaZ Gong, L J Medeiros, J E Cortes, et al.
Pageof 5